VEA
RCKT icon

Virtus ETF Advisers’s Rocket Pharmaceuticals RCKT Stock Holding History

Virtus ETF Advisers’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,656
Closed -$71.1K – 710
2024
Q4 		$71.1K Buy
5,656
+1,628
+40% +$24.5K 0.03% 363
2024
Q3 		$74.4K Buy
4,028
+68
+2% +$1.39K 0.03% 419
2024
Q2 		$85.3K Buy
3,960
+897
+29% +$20.6K 0.04% 381
2024
Q1 		$82.5K Sell
3,063
-211
-6% -$5.99K 0.04% 389
2023
Q4 		$98.1K Sell
3,274
-1,082
-25% -$23.9K 0.06% 367
2023
Q3 		$89.3K Sell
4,356
-436
-9% -$7.92K 0.05% 349
2023
Q2 		$95.2K Buy
4,792
+351
+8% +$7.09K 0.06% 407
2023
Q1 		$76.1K Sell
4,441
-1,713
-28% -$33.5K 0.04% 391
2022
Q4 		$120K Sell
6,154
-3,706
-38% -$68.2K 0.06% 413
2022
Q3 		$157K Buy
9,860
+68
+0.7% +$1.06K 0.06% 347
2022
Q2 		$135K Buy
9,792
+3,000
+44% +$35.8K 0.05% 339
2022
Q1 		$108K Sell
6,792
-400
-6% -$6.91K 0.05% 290
2021
Q4 		$157K Buy
7,192
+2,686
+60% +$73.3K 0.06% 336
2021
Q3 		$135K Sell
4,506
-228
-5% -$8.3K 0.06% 358
2021
Q2 		$210K Sell
4,734
-627
-12% -$27.2K 0.09% 312
2021
Q1 		$238K Buy
5,361
+100
+2% +$5.49K 0.1% 296
2020
Q4 		$289K Sell
5,261
-11,734
-69% -$428K 0.12% 230
2020
Q3 		$389K Sell
16,995
-2,315
-12% -$57K 0.2% 174
2020
Q2 		$404K Buy
19,310
+2,895
+18% +$52.2K 0.19% 193
2020
Q1 		$229K Sell
16,415
-2,391
-13% -$47.3K 0.09% 269
2019
Q4 		$428K Buy
18,806
+3,143
+20% +$52.5K 0.07% 235
2019
Q3 		$182K Sell
15,663
-872
-5% -$10.8K 0.04% 261
2019
Q2 		$248K Sell
16,535
-1,264
-7% -$22.1K 0.05% 277
2019
Q1 		$312K Sell
17,799
-1,805
-9% -$28.5K 0.66% 57
2018
Q4 		$291K Sell
19,604
-2,170
-10% -$36K 0.05% 119
2018
Q3 		$536K Sell
21,774
-15,976
-42% -$347K 0.06% 115
2018
Q2 		$741K Buy
+37,750
New +$714K 0.66% 75

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Virtus ETF Advisers's RCKT Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 5,656 shares — an estimated $71.1K sold.

Virtus ETF Advisers first reported a position in RCKT in Q2 2018 and held it in 27 quarters. The position peaked at $741K in Q2 2018. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,656 Rocket Pharmaceuticals shares in Q1 2025, an estimated $71.1K.
  • Virtus ETF Advisers first reported a position in Rocket Pharmaceuticals in Q2 2018 and held it in 27 quarters.
  • Virtus ETF Advisers's Rocket Pharmaceuticals position peaked at $741K in Q2 2018.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.